Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2022-06-29 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
关于完成工商变更登记和公司章程备案的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the completion of industrial and commercial registration changes and the filing of the company's Articles of Association. It details the reduction of registered capital, approval of related board and shareholder meetings, and the completion of official registration and filing with the market supervision bureau. The document is relatively short (1172 characters) and primarily serves as a formal notice of completed corporate governance and capital structure changes, including the filing of amended company bylaws. It does not contain detailed financial statements or comprehensive financial analysis. Therefore, it is not an Annual Report, Interim Report, or similar financial report. It is also not a report publication announcement since it contains substantive information about the changes. The content fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-06-29 Chinese
回购股份注销完成暨股份变动公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the completion of share repurchase and cancellation, including details on the number of shares repurchased, the price adjustments, and the resulting changes in share capital structure. It includes legal opinions, board and supervisory approvals, and mentions the completion of registration procedures. The document length is 1750 characters, which is relatively short and focused on a specific corporate action related to shares. This fits the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback and cancellation of its own shares. It is not an annual or interim report, nor a general regulatory filing or announcement of a report publication. Therefore, the correct classification is POS with high confidence.
2022-06-22 Chinese
2021年度权益分派公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2021 annual equity distribution (dividend) by Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the dividend amount, payment dates, tax treatment, and record dates. The document is short (1290 characters) and focuses on dividend distribution specifics rather than presenting financial statements or comprehensive financial results. It is not a full annual report or earnings release but an announcement of dividend payment details. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-05-08 Chinese
第三届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the 12th meeting of the 3rd Supervisory Board of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, and the approval of the company's 2022 first quarter report. The document does not contain the actual financial data or the full quarterly report itself but rather the Supervisory Board's resolution approving the report and confirming its compliance with regulations. The document length is short (1083 characters) and it references the first quarter report being published on the Beijing Stock Exchange website with a separate announcement number. This fits the pattern of a Regulatory Filing (RNS) as it is an official announcement related to regulatory compliance and meeting resolutions, not the report itself. Therefore, the correct classification is Regulatory Filings (RNS).
2022-04-26 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled "江苏德源药业股份有限公司章程" which translates to "Articles of Association of Jiangsu Deyuan Pharmaceutical Co., Ltd." It contains detailed chapters and sections about the company's organizational structure, shareholder rights, board of directors, management, financial accounting systems, profit distribution, auditing, and other governance-related matters. The content includes legal references to Chinese company law, securities law, and stock exchange regulations. It is a comprehensive governance document outlining the internal rules and regulations of the company rather than a financial report, announcement, or meeting material. There is no indication that this is an annual report, earnings release, proxy statement, or any other type of financial or regulatory filing. The document is lengthy (15,000 characters) and substantive, not a brief announcement or certification. Therefore, the most appropriate classification is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-04-26 Chinese
关于减少注册资本通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the reduction of registered capital due to the repurchase and cancellation of restricted shares. It includes details about the board and shareholder approvals, legal references, and instructions for creditors to claim debts or provide guarantees within a specified period. The document is a formal notification to creditors about the capital reduction and related procedures, not a financial report or detailed financial data. It is an official announcement related to capital structure changes but does not report new financing or fundraising activities. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding capital changes such as share repurchases or reductions in registered capital.
2022-04-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.